Clinical Factors Predictive For Efficacy Of Treatment With Cabazitaxel In Metastatic Castration Resistant Prostate Cancer (Mcrpc) In Second And Later Lines.

e16511Background: Several newtreatment options for patients with mCRPC have been approved within the last years - among them cabazitaxel, abiraterone acetate, enzalutamide, and radium-223. No factors predictive for efficacy are known and the optimal treatment sequence has yet to be defined. Methods: We analyzed all patients with mCRPC treated with cabazitaxel at our institution between 2011 and 2016. Data were retrieved retrospectively from the prospective electronical patient chart. Results: 38 patients received cabazitaxel (29 % 2nd line, 37 % 3rd line, 34 % u003e 3rd line). Treatment was generally well tolerated with an average of 4.76 cycles (range 1-11) and a treatment duration of 2.95 months (range 0-8). In 2 patients treatment was discontinueddue to toxicity. 22 patients were still alive with a median follow-up time of 7 months calculated from end of cabazitaxel treatment (range 0-34). Median progression free survival (PFS) was 4.03 months (95% CI 0.625 – 7.441). Median overall survival (OS) was 12.13 ...